Age 4–11 |
Formoterol-treated patients | 3263 | 1.29 | 2169/1094 | 9 | 2725/538 | 38 (1.16) | |
Non-LABA-treated patients | 2165 | 0.92 | 1411/754 | 9 | 1698/467 | 24 (1.11) | |
Total | 5428 | 2.21 | 3580/1848 | 9 | 4423/1005 | 62 (1.14) | 1.05 (0.61 to 1.83) |
Age 12–17 |
Formoterol-treated patients | 4533 | 2.24 | 2675/1856† | 14 | 3955/578 | 23 (0.51) | |
Non-LABA-treated patients | 1888 | 0.97 | 1111/777 | 14 | 1561/527 | 16 (0.85) | |
Total | 6421 | 3.21 | 3786/2633 | 14 | 5316/1105 | 39 (0.61) | 0.60 (0.30 to 1.21) |
All trials combined |
Formoterol-treated patients | 7796 | 3.52 | 4844/2950 | 12 | 6680/1116 | 61 (0.78) | |
Non-LABA-treated patients | 4053 | 1.89 | 2522/1531 | 12 | 3059/994 | 40 (0.99) | |
Total, all trials | 11849 | 5.41 | 7366/4481 | 12 | 9739/2110 | 101 (0.85) | 0.79 (0.52 to 1.21) |